Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.8 USD | +1.49% | +7.29% | +18.61% |
05-07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
05-07 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.61% | 5.49B | |
+4.80% | 109B | |
+11.69% | 105B | |
+0.41% | 22.25B | |
-11.80% | 22.09B | |
-7.89% | 18.68B | |
-38.36% | 17.58B | |
-9.58% | 16.85B | |
+4.96% | 13.76B | |
+36.96% | 12.46B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics Says Roche Gets European Commission's Approval for Tecentriq SC